CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

Prior treatment

• Patients with history of allogeneic HSCT but PBMNC is not available from prior- transplant donor for preparation of CAR T cells and peripheral blood tumour load \>30%; patients without history of allogeneic HSCT and peripheral blood tumour load \>30%;
• Organ transplantation (excluding haematopoietic stem cell transplantation) history;

Other illness

• Intracranial hypertension or cerebral impaired consciousness;
• Symptomatic heart failure or severe arrhythmia;
• Symptoms of severe respiratory failure;
• With other types of malignancy;
• With sepsis or other uncontrollable infection;
• Suffering from uncontrollable diabetes mellitus;
• Severe mental disorders;
• Hepatitis (including hepatitis B and C) and positive screening for AIDS and syphilis.

Lab values

• Serum creatinine and/or urea nitrogen ≥ 1.5 times the normal value;

Other

• Diffuse intravascular coagulation;
• Have significant intracranial lesions on cranial MRI;
• Female patients (patients of childbearing potential) with positive blood HCG test;

• Relapsed or refractory CD7-positive T-cell lymphomas that were treated with with standard chemotherapy, with poor prognosis from currently available treatments at and no available treatment options (e.g., HSCT or chemotherapy);
• Male or female, age 14-70;
• Eastern Cooperative Oncology Group (ECOG) Physical Status Score 0-2;
• life expectancy is at least 60 days;
• Subjects should be capable of understanding and signing the informed consent form prior to any screening procedures. Subjects are willing to follow the study visit schedule and associated study procedures as specified in the protocol. Candidates between the ages of 19-70 years old will need to be sufficiently aware of and capable of signing the informed consent form; underage candidates between the ages of 14-18 years old will need to be sufficiently aware of the informed consent form and their legal guardian will also need to sign the informed consent form separately.